治疗外阴阴道念珠菌病的新型抗真菌药:我们在哪里?

IF 4 4区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases Pub Date : 2022-01-01 DOI:10.17925/id.2022.1.1.16

A. Gamal, A. Kadry, M. Elshaer, M. Ghannoum

{"title":"治疗外阴阴道念珠菌病的新型抗真菌药:我们在哪里?","authors":"A. Gamal, A. Kadry, M. Elshaer, M. Ghannoum","doi":"10.17925/id.2022.1.1.16","DOIUrl":null,"url":null,"abstract":"Vulvovaginal candidiasis (VVC) is a common health-related issue and the second most common cause of vaginitis. Previously, azole antifungals were the mainstay of VVC treatment. Additionally, boric acid and nystatin have been used topically for management of VVC. Despite being effective and well tolerated by most patients, the use of azoles may be limited in some cases. Currently, two new antifungal agents have received US Food and Drug Administration approval for use in the management of VVC. In this article, we briefly review treatment regimens used for the management of VVC over the past decade, the newly approved agents and their possible clinical application, and future treatment considerations.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"1 1","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?\",\"authors\":\"A. Gamal, A. Kadry, M. Elshaer, M. Ghannoum\",\"doi\":\"10.17925/id.2022.1.1.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vulvovaginal candidiasis (VVC) is a common health-related issue and the second most common cause of vaginitis. Previously, azole antifungals were the mainstay of VVC treatment. Additionally, boric acid and nystatin have been used topically for management of VVC. Despite being effective and well tolerated by most patients, the use of azoles may be limited in some cases. Currently, two new antifungal agents have received US Food and Drug Administration approval for use in the management of VVC. In this article, we briefly review treatment regimens used for the management of VVC over the past decade, the newly approved agents and their possible clinical application, and future treatment considerations.\",\"PeriodicalId\":13671,\"journal\":{\"name\":\"Infectious Diseases\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17925/id.2022.1.1.16\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17925/id.2022.1.1.16","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

外阴阴道念珠菌病(VVC)是一种常见的健康相关问题，也是阴道炎的第二大常见原因。以前，唑类抗真菌药物是VVC治疗的主要药物。此外，硼酸和制霉菌素已被局部用于VVC的治疗。尽管对大多数患者有效且耐受性良好，但在某些情况下，唑类药物的使用可能受到限制。目前，两种新的抗真菌药物已获得美国食品和药物管理局批准用于VVC的管理。在本文中，我们简要回顾了过去十年来用于VVC治疗的治疗方案，新批准的药物及其可能的临床应用，以及未来治疗的考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?

Vulvovaginal candidiasis (VVC) is a common health-related issue and the second most common cause of vaginitis. Previously, azole antifungals were the mainstay of VVC treatment. Additionally, boric acid and nystatin have been used topically for management of VVC. Despite being effective and well tolerated by most patients, the use of azoles may be limited in some cases. Currently, two new antifungal agents have received US Food and Drug Administration approval for use in the management of VVC. In this article, we briefly review treatment regimens used for the management of VVC over the past decade, the newly approved agents and their possible clinical application, and future treatment considerations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Infectious Diseases INFECTIOUS DISEASES-

CiteScore

8.20

自引率

1.70%

发文量

审稿时长

8 weeks

期刊介绍： Infectious Diseases (formerly Scandinavian Journal of Infectious Diseases) is a peer-reviewed journal publishing articles on all aspects of human infection, including pathogenesis, diagnosis, and treatment of infectious diseases, and also on medical microbiology and epidemiology